Gene therapy of cancer: activation of nucleoside prodrugs with e. colipurine nucleoside phosphorylase

Article abstract of DOI:10.1080/15257779908041562

During the last few years, many gene therapy strategies have been developed for various disease targets. The development of anticancer gene therapy strategies to selectively generate cytotoxic nucleoside or nucleotide analogs is an attractive goal. One such approach involves the delivery of herpes simplex virus thymidine kinase followed by the acyclic nucleoside analog ganciclovir. We have developed another gene therapy methodology for the treatment of cancer that has several significant attributes. Specifically, our approach involves the delivery of E. coli purine nucleoside phosphorylase, followed by treatment with a relatively non-toxic nucleoside prodrug that is cleaved by the enzyme to a toxic compound. .This presentation describes the concept, details our search for suitable prodrugs, and summarizes the current biological data. Copyright

Full text of DOI:10.1080/15257779908041562

This article was downloaded by: [University of Guelph]
On: 19 August 2012, At: 23:28
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered
office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK
Nucleosides and Nucleotides
Publication details, including instructions for authors and
subscription information:
http://www.tandfonline.com/loi/lncn19
Gene Therapy of Cancer: Activation of
Nucleoside Prodrugs with E. coli Purine
Nucleoside Phosphorylase
John A. Secrist III a , William B. Parker a , Paula W. Allan a , L. Lee
Bennett Jr. a , William R. Waud a , Jackie W. Truss a , Anita T. Fowler
a , John A. Montgomery a , Steven E. Ealick b , Alan H. Wells c , G.
Yancey Gillespie c , V. K. Gadi c & Eric J. Sorscher c
a Southern Research Institute, Birmingham, Alabama, USA
b Cornell University, Ithaca, New York, USA
c University of Alabama at Birmingham, Birmingham, Alabama, USA
Version of record first published: 04 Oct 2006
To cite this article: John A. Secrist III, William B. Parker, Paula W. Allan, L. Lee Bennett Jr., William
R. Waud, Jackie W. Truss, Anita T. Fowler, John A. Montgomery, Steven E. Ealick, Alan H. Wells,
G. Yancey Gillespie, V. K. Gadi & Eric J. Sorscher (1999): Gene Therapy of Cancer: Activation of
Nucleoside Prodrugs with E. coli Purine Nucleoside Phosphorylase, Nucleosides and Nucleotides,
18:4-5, 745-757
To link to this article: http://dx.doi.org/10.1080/15257779908041562
PLEASE SCROLL DOWN FOR ARTICLE
Full terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions
This article may be used for research, teaching, and private study purposes. Any
substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing,
systematic supply, or distribution in any form to anyone is expressly forbidden.
The publisher does not give any warranty express or implied or make any representation
that the contents will be complete or accurate or up to date. The accuracy of any
instructions, formulae, and drug doses should be independently verified with primary
sources. The publisher shall not be liable for any loss, actions, claims, proceedings,
demand, or costs or damages whatsoever or howsoever caused arising directly or
indirectly in connection with or arising out of the use of this material.